A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
Phase of Trial: Phase III
Latest Information Update: 04 Jul 2019
Price : $35 *
At a glance
- Drugs Levetiracetam (Primary)
- Indications Mild cognitive impairment
- Focus Registrational; Therapeutic Use
- Acronyms HOPE4MCI
- Sponsors AgeneBio
- 17 Jan 2019 According to an AgeneBio media release, first patient has been enrolled.
- 18 Oct 2018 Planned End Date changed from 1 Sep 2022 to 1 Nov 2022.
- 18 Oct 2018 Planned primary completion date changed from 1 Sep 2021 to 1 Nov 2021.